Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.
about
Absolute oral bioavailability of ciprofloxacinComparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare.Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States.Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patientsCommonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics.Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers.Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects.Sucralfate significantly reduces ciprofloxacin concentrations in serum.Investigation of potential interaction of ciprofloxacin with cyclosporine in bone marrow transplant recipientsCiprofloxacin activity in cyst fluid from polycystic kidneys.Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections.Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in womenCiprofloxacin pharmacokinetics in patients with normal and impaired renal functionThe fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.Tissue penetration of ciprofloxacin after single and multiple doses.Ciprofloxacin in the treatment of pneumonia.Bactericidal activity of ciprofloxacin against amikacin- and cefotaxime-resistant gram-negative bacilli and methicillin-resistant staphylococci.Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men.Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model.Mechanisms of resistance to quinolones.Ciprofloxacin biliary disposition in cholecystectomised patients with special references to HPLC and bioassay data.Mutant selection window hypothesis updated.Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in miceUse of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic studySteady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa.Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disksImpact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection.Detection of Ciprofloxacin in Urine through Sensitized Lanthanide Luminescence.Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones.Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers.A Qualitative Review on the Pharmacokinetics of Antibiotics in Saliva: Implications on Clinical Pharmacokinetic Monitoring in Humans.Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions.Treatment of gram-negative infections in patients with renal impairment: new alternatives to aminoglycosides.The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics.Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacinSchedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy.Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers
P2860
Q24685241-6836AC78-67CF-4780-81EF-DCC6A1D01806Q28360184-3DC8DBE7-64C2-42CF-BB41-9C0192D1EF1DQ33980574-49674A8F-2EAC-4EEC-8F89-F7CBB1CF3ADCQ33983228-90C07415-8B73-45DF-8E24-E150D78A0803Q34437719-C47D89D1-18B1-4FCE-AAED-C11CC430D877Q35114178-FA650E80-056B-494F-A4B6-6B33A93CA7F6Q35191364-498DD670-C3B0-4805-994C-752A1DEFA2E3Q35253425-C7BC76A8-FC5E-44AE-A91C-BEA563D1BB54Q35256183-05C9C6AC-2980-4A85-86F1-DAF8958E3714Q35259368-653568A7-7408-4EBD-8576-BAFB20A543CAQ35308712-5C7775D1-59FD-4EC0-B02A-E0E2972B775CQ35536165-C3F0BB55-6CB9-4FA7-919F-2D96ECD9871DQ35536186-1812867B-357F-4086-A6E7-7043E91D576BQ35537357-96D86E06-4FE5-4DB9-B871-EDF8FAF90F80Q35539825-9B366FC2-08C7-479A-944E-F4040CA4B24FQ35572870-05E35035-91CE-4506-B408-61464F2C0685Q35649002-0CDBA130-E831-4A8E-AC51-2C55871404B9Q35650590-B8EB2ADC-4DAB-4470-B0B0-DF39AB137180Q35650708-456C96CF-6CCD-4FBA-B40D-3D75ADE48FB0Q35651395-FA60AAF1-6D42-450B-913A-172F3FB01E3DQ35808500-FE0ACBF1-4BC5-405B-A56F-9B543AA42C6FQ36155441-E897EA4C-021F-4B55-8F10-361313ED98E9Q36474398-7E2D242D-AC69-4A6C-8A8D-45F8A09F40B5Q36728061-08B2AC43-FE32-46B3-9812-7C140878C5EFQ36753658-F59868EC-64E5-4774-8942-65E0C7D2957DQ36754888-6FEFC518-A244-4781-BB18-86A1F50C416AQ36757441-C2885AEF-C2F3-4721-B4D5-8B6C6B55B0C3Q37281766-FC6959D1-D023-4A12-B49C-A9F6003025B2Q37392904-732433D4-073B-47DB-933C-17FF63BBDD7BQ37537434-2FD18E01-7790-44FD-95D0-98E2D47D157DQ38271416-4C3A3B35-1F4E-4642-A21D-26D84FCC6525Q38520641-5CBF838C-CBF6-4198-A0B8-7FC27DAD0AB2Q38582536-6672CFE5-C18F-4685-B46A-E1BFADEE9CEBQ39214819-FD9A08B7-9DB5-4766-B617-EB7C3FB5AADCQ39558431-2343A433-CE0B-432A-B28E-7D800B49A893Q39637673-7A9EE17D-A954-4351-8AD5-544F53AD2EFEQ39698735-49A34BB1-1E23-44C7-92C0-B9C5C1D2FEFFQ39716863-7F9BC4D1-F937-4017-B551-4AD79D0DF60FQ39730719-22A00758-246F-444E-9E8B-D30D1D8E68C5Q39816080-B92214F3-EC53-47F5-8317-760A0DCC0088
P2860
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.
@ast
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.
@en
type
label
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.
@ast
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.
@en
prefLabel
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.
@ast
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.
@en
P2093
P356
P1476
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.
@en
P2093
Gonzalez MA
Welling PG
P2860
P304
P356
10.1128/AAC.26.5.741
P407
P577
1984-11-01T00:00:00Z